Hyperhomocysteinemia, Oxidative Stress, and Cerebral Vascular Dysfunction

Stroke

Volumn 35, Issue 2, 2004, Pages 345-347

  Faraci, Frank M ^a   Lentz, Steven R ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Advances in Stroke; Hyperhomocysteinemia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTIOXIDANT; ARGININE DERIVATIVE; CHOLINE; COPPER; CYSTATHIONINE BETA SYNTHASE; DIMETHYLARGININASE; FOLIC ACID; HOMOCYSTEINE; ISOENZYME; METHIONINE; METHIONINE SYNTHASE; N(G),N(G) DIMETHYLARGININE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; S ADENOSYLHOMOCYSTEINE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AMINO ACID METABOLISM; ATHEROSCLEROSIS; BIOSYNTHESIS; BRAIN BLOOD FLOW; BRAIN MICROCIRCULATION; CAROTID ARTERY DISEASE; CEREBROVASCULAR DISEASE; DIETARY INTAKE; DISEASE ASSOCIATION; DNA METHYLATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; MULTIINFARCT DEMENTIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SHORT SURVEY; STROKE; TISSUE STRUCTURE; VASCULAR ENDOTHELIUM;

ARGININE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; DNA METHYLATION; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 0842289223     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000115161.10646.67     Document Type: Short Survey

References (30)

1. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 1996;98:24-29.
2. Faraci FM. Hyperhomocysteinemia: a million ways to lose control. Arterioscler Thromb Vasc Biol. 2003;23:371-373.
3. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, Koller A. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of TNFα, NAD(P)H oxidase and iNOS. Arterioscler Thromb Vasc Biol. 2003;23:418-424.
4. Loscalzo J. Oxidant stress: a key determinant of atherothrombosis. Biochem Soc Trans. 2003;31:1059-1061.
5. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest. 2000;106:483-491.
6. Lentz SR, Erger RA, Dayal S, Maeda N, Malinow MR, Heistad DD, Faraci FM. Folate dependence of hyperhomocysteinemia and endothelial dysfunction in cystathionine β-synthase-deficient mice. Am J Physiol. 2000;279:H970-H975.
7. De Bree A, Verschuren WMM, Kromhout D, Kluijtmans LAJ, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev. 2002;54:599-618.
8. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol. 2003;2:425-428.
9. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PWF, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
10. Mcllroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore P. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer's disease in Northern Ireland. Stroke, 2002;33:2351-2356.
11. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA. 2002;288:2015-2022.
12. Zhang F, Slungaarg A, Vercellotti GM, Iadecola C. Superoxide-dependent cerebrovascular effects of homocysteine. Am J Physiol. 1998;274:R1704-R1711.
13. Symons JD, Mullick AE, Ensunsa JL, Ma AA, Rutledge JC. Hyperhomocysteinemia evoked by folate depletion: effects on coronary and carotid arterial function. Arterioscler Thromb Vasc Biol. 2002;22:772-780.
14. Chao C-L, Lee Y-T. Impairment of cerebrovascular reactivity by methione-induced hyperhomocysteinemia and amelioration by quinapril treatment. Stroke. 2000;31:2907-2911.
15. Volpe M, Iaccarino G, Vecchione C, Rizzoni D, Russo R, Rubattu S, Condorelli G, Ganten U, Ganten D, Trimarco B, Lindpainter K. Association and cosegregation of stroke with impaired endothelium-dependent vasorelaxation in stroke prone, spontaneously hypertensive rats. J Clin Invest. 1996;98:256-261.
16. Ganz P, Vita JA. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation. 2003;108:2049-2053.
17. Gilfix BM. Hyperhomocysteinemia: genetic determinants and selected mouse models. Clin Invest Med. 2003;26:121-132.
18. Devlin AM, Bottiglieri T, Faraci FM, Rozen R, Lentz SR. Effect of MTHFR genotype on diet-induced hyperhomocysteinemia and vascular function in mice. Blood. In press.
19. Lentz SR, Dayal S, Arning E, Bottiglieri T, Sigmund CD, Faraci FM. Role of superoxide in cerebral vascular dysfunction in hyperhomocysteinemic mice. Circulation. 2002;106:11-111. Abstract.
20. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffrey S, Bamford JM, Markus HS. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 2004;127:1-8.
21. Baumbach GL, Sigmund CD, Bottiglieri T, Lentz SR. Structure of cerebral arterioles in cystathionine β-synthase-deficient mice. Circ Res. 2002;91:931-937.
22. Kim J-M, Lee H, Chang N. Hyperhomocysteinemia due to short-term folate deprivation is related to electron microscopic changes in the rat brain. J Nutr. 2002;132:3418-3421.
23. Soriano FG, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murphy KGK, Salzman AL, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nature Med. 2001;17:108-113.
24. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci. 2000;20:6920-6926.
25. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003;59:824-833.
26. Faraci FM, Brian JE, Heistad DD. Responses of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol. 1995;269:H1522-H1527.
27. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, Szuba A, Malinow MR, Wascher TC, Pachinger O, Cooke JP. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation. 2003;108:933-938.
28. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000;20:1557-1564.
29. Hiltunen MO, Yla-Herttuala S. DNA methylation, smooth muscle cells and atherogenesis. Arterioscler Thromb Vasc Biol. 2003;23:1750-1753.
30. Dong C, Yoon W, Goldschmidt-Clermont PJ. DNA methylation and atherosclerosis. J Nutr. 2002;132:2406S-2409S.